Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without Immunotherapy (INTROSPECTION)
Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without Immunotherapy Ocena Efektu immunomodulującego Radioterapii Paliatywnej, w Tym Radioterapii z Przestrzennym zróżnicowaniem Dawki, Podanej Samodzielnie Lub z immunoterapią, u Chorych którzy Wyczerpali możliwość Leczenia Systemowego i Radioterapii Radykalnej, Przy Wykorzystaniu Immuno-PET i badań Proteomicznych
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Sławomir Blamek, MD, PhD, MBA
- Phone Number: +48322788052
- Email: slawomir.blamek@gliwice.nio.gov.pl
Study Contact Backup
- Name: Marzena Gawkowska, MD, PhD
- Phone Number: +48322788625
- Email: marzena.gawkowska@gliwice.nio.gov.pl
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Pathologically confirmed diagnosis of clear cell renal cell carcinoma, melanoma, cervical cancer, endometrial cancer or triple negative breast cancer.
- Patients nnot eligible for radical treatment with radiotherapy (including stereotactic radiotherapy of the tumor in the potential planned area of irradiation in the study), chemotherapy and palliative immunotherapy in accordance with applicable national standards but who qualify for palliative radiation treatment
- General condition according to Karnofsky scale: 60-100
- Patients with tumor (index lesion) larger than 5 cm in size that can be irradiated with either SHORT or SFRT technique (presence of other tumors that may be independently treated locally is not an exclusion criterion)
- The tumor may be assessed using iRECIST
- Age over 18 years
- Granted written, informed consent to participate in the research experiment
- No contraindications to treatment with Pembrolizumab (according to the information provided in the product characteristics).
- Expected survival time over 6 months.
Exclusion criteria
- Lack of consent to participate in the experiment
- Contraindications to Pembrolizumab according to the product characteristics
- Pregnancy and lactation
- Inability of the patient to cooperate, including claustrophobia that prevents imaging tests from being performed as planned.
- Women of childbearing potential who are unwilling or unable to use an acceptable method of contraception to avoid pregnancy throughout treatment and for 5 months after its completion.
- Condition after organ transplantation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: SFRT with immunotherapy
|
Diagnostic imaging with novel radiotracer - drug (Pembrolizumab) labeled with zirconium-89
Assessment of the proteomic profile before and periodically after treatment
|
|
Active Comparator: SHORT with immunotherapy
|
Diagnostic imaging with novel radiotracer - drug (Pembrolizumab) labeled with zirconium-89
Assessment of the proteomic profile before and periodically after treatment
|
|
Experimental: SFRT
|
Diagnostic imaging with novel radiotracer - drug (Pembrolizumab) labeled with zirconium-89
Assessment of the proteomic profile before and periodically after treatment
Diagnostic imaging with novel radiotracer - drug (Pembrolizumab) labeled with zirconium-89 after radiotherapy performed in patients who are not treated with immunotherapy
|
|
Active Comparator: SHORT
|
Diagnostic imaging with novel radiotracer - drug (Pembrolizumab) labeled with zirconium-89
Assessment of the proteomic profile before and periodically after treatment
Diagnostic imaging with novel radiotracer - drug (Pembrolizumab) labeled with zirconium-89 after radiotherapy performed in patients who are not treated with immunotherapy
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in expression of PD-1 receptors expressed as a ratio of SUV values
Time Frame: one year
|
The expression of PD-1 receptors will be measured with Immuno-PET basing on Zr-89 labeled Pembrolizumab and expressed as the ratio of initial and post-treatment SUV
|
one year
|
|
Change in number of areas with PD-1 receptors expressed as number of lesions
Time Frame: one year
|
The localization of regions expressing PD-1 receptors will be identified with Immuno-PET basing on Zr-89 labeled Pembrolizumab and expressed as the number of lesions
|
one year
|
|
Change of proteome expression profile after treatment expressed in NPX (Normalized Protein eXpression) values
Time Frame: one year
|
The difference between proteome expression profile before treatment and after the last infusion of Pembrolizumab or after a year in arms without immunotherapy.
The Proximity Extension Assay (PEA) technology will be used.
Following sequencing, the raw data will be converted to counts, assigning an integer value to each assay-sample combination based on the detected copy numbers.
These raw data counts will be converted into NPX values, enabling the identification of protein level changes within different sample sets, and establishing protein signatures.
|
one year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Sławomir Blamek, MD, PhD, MBA, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Male Urogenital Diseases
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Neoplasms by Histologic Type
- Uterine Diseases
- Genital Diseases, Female
- Neoplasms, Glandular and Epithelial
- Adenocarcinoma
- Genital Neoplasms, Female
- Skin Diseases
- Breast Diseases
- Urologic Neoplasms
- Carcinoma
- Uterine Cervical Diseases
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Kidney Neoplasms
- Uterine Neoplasms
- Neuroendocrine Tumors
- Nevi and Melanomas
- Skin Neoplasms
- Breast Neoplasms
- Carcinoma, Renal Cell
- Uterine Cervical Neoplasms
- Melanoma
- Triple Negative Breast Neoplasms
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Antineoplastic Agents
- Molecular Mechanisms of Pharmacological Action
- Pembrolizumab
Other Study ID Numbers
Other Study ID Numbers
- 23/ABM/01/00078
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.